Alzheimer’s disease is a neurodegenerative disease characterized by extracellular amyloid-β (Aβ) plaques and intracellular neurofibrillary tangles containing pathological tau protein aggregates. Even though both, Aβ and tau, are related to Alzheimer’s disease, studies have shown that the degree of tau-related pathology correlates better with the degree of dementia than the amyloid plaque burden. Human tau, which exists in six isoforms of different length, is used in cerebrospinal fluid as a sensitive and specific biomarker for Alzheimer’s disease, usually determined by ELISA.

In addition to our catalog portfolio of over 250 Alzheimer’s disease related research products, Bachem now offers a comprehensive choice of tau peptides including phosphorylated sequences as new catalog products.

**Tau Protein**

Microtubules are part of the cytoskeleton, tubulin polymers with various cellular tasks. For instance, they play a role in stabilizing cell shape and during mitosis, and act as tracks for intracellular transport by motor proteins. Microtubules are stabilized by various types of microtubule-associated proteins which bind to their surface and promote their self-assembly from tubulin subunits. Tau (Microtubule-Associated Protein Tau, MAPT) \[1\] stabilizes the microtubules of the neuronal cytoskeleton and thus is important for their regular function. Tau protein is primarily expressed in neuronal cell bodies and axons.

The binding affinity of tau for microtubules is regulated by the phosphorylation state of the protein. In healthy neurons, the protein is phosphorylated by a number of kinases and dephosphorylated by phosphatases \[2,3\]. An equilibrium of phosphorylated and non-phosphorylated forms serving as tau pool exists in the cytosol. Phosphorylation is reverted when tau binds to tubulin. Glycogen-synthase kinase-3β (GSK-3β), cyclin-dependent protein kinase 5 (cdk5), and cAMP-dependent protein kinase (PKA) are amongst the most important tau kinases \[4\]. Protein phosphatase PP2A was found to be the major tau phosphatase \[3,5\]. In Alzheimer’s disease (AD) or other pathological conditions known as tauopathies, phosphorylation of the protein is dysregulated leading to a decrease of the tubulin-
binding capacity. Whereas the microtubules are destabilized, hyperphosphorylated tau protein aggregates yielding the so-called neurofibrillary tangles (NFTs), one of the hallmarks of AD [6-9]. In NFTs, the extent of tau phosphorylation was found to be 3 to 4 times higher than in cytosolic tau of healthy and AD brains [10].

Tau is a rather disordered highly flexible protein. Due to its random coil conformation crystals of the protein could not be obtained

Table 1: Isoforms of human Tau protein (N insert, R repeat).

<table>
<thead>
<tr>
<th>Clone*</th>
<th>Inserts/Repeats</th>
<th>Number of AA</th>
<th>MW (kDa)</th>
<th>Sequence</th>
</tr>
</thead>
<tbody>
<tr>
<td>htau23 (fetal tau)</td>
<td>0N/3R</td>
<td>352</td>
<td>36.7</td>
<td>MAEPRQFEVMEDHAGTYGLGDRKDQGYTMHDQEGDTHDAKLAAEAGITDPSLEDEAAGHVTQR-VMSKSKDGTGSDDKKAKAGDKTIATPRGAAAPPOGKQQAANATRAPKTPPSSPSGKPGS-&lt;br&gt;DDKSGSAPQGKQANATRIAPKTPPPSSEPKSGDSGYSPSGPTPSGSRSTLPSTLPKPVVRTPPKPSSSASLRTQAPVPMILNViK-NHPPGGQQVQIVKPVDSKTVSCGSLGNIHHKPGGGQVEKSEKLDKDFVQSKIG-SLDNITHVGGQGNNKIEKTHKLTFRENAAKTDHGAEVYKSVGSVPDSPRHLNSVSTGSDMVDSPQ-LADEVSASLAKGL</td>
</tr>
<tr>
<td>htau37</td>
<td>1N/3R</td>
<td>381</td>
<td>39.7</td>
<td>MAEPRQFEVMEDHAGTYGLGDRKDQGYTMHDQEGDTHDAKLAAEAGITDPSLEDEAAGHVTQR-VMSKSKDGTGSDDKKAKAGDKTIATPRGAAAPPOGKQQAANATRAPKTPPSSPSGKPGS-&lt;br&gt;DDKSGSAPQGKQANATRIAPKTPPPSSEPKSGDSGYSPSGPTPSGSRSTLPSTLPKPVVRTPPKPSSSASLRTQAPVPMILNViK-NHPPGGQQVQIVKPVDSKTVSCGSLGNIHHKPGGGQVEKSEKLDKDFVQSKIG-SLDNITHVGGQGNNKIEKTHKLTFRENAAKTDHGAEVYKSVGSVPDSPRHLNSVSTGSDMVDSPQ-LADEVSASLAKGL</td>
</tr>
<tr>
<td>htau39</td>
<td>2N/3R</td>
<td>410</td>
<td>42.6</td>
<td>MAEPRQFEVMEDHAGTYGLGDRKDQGYTMHDQEGDTHDAKLAAEAGITDPSLEDEAAGHVTQR-VMSKSKDGTGSDDKKAKAGDKTIATPRGAAAPPOGKQQAANATRAPKTPPSSPSGKPGS-&lt;br&gt;DDKSGSAPQGKQANATRIAPKTPPPSSEPKSGDSGYSPSGPTPSGSRSTLPSTLPKPVVRTPPKPSSSASLRTQAPVPMILNViK-NHPPGGQQVQIVKPVDSKTVSCGSLGNIHHKPGGGQVEKSEKLDKDFVQSKIG-SLDNITHVGGQGNNKIEKTHKLTFRENAAKTDHGAEVYKSVGSVPDSPRHLNSVSTGSDMVDSPQ-LADEVSASLAKGL</td>
</tr>
<tr>
<td>htau24</td>
<td>0N/4R</td>
<td>383</td>
<td>41.0</td>
<td>MAEPRQFEVMEDHAGTYGLGDRKDQGYTMHDQEGDTHDAKLAAEAGITDPSLEDEAAGHVTQR-VMSKSKDGTGSDDKKAKAGDKTIATPRGAAAPPOGKQQAANATRAPKTPPSSPSGKPGS-&lt;br&gt;DDKSGSAPQGKQANATRIAPKTPPPSSEPKSGDSGYSPSGPTPSGSRSTLPSTLPKPVVRTPPKPSSSASLRTQAPVPMILNViK-NHPPGGQQVQIVKPVDSKTVSCGSLGNIHHKPGGGQVEKSEKLDKDFVQSKIG-SLDNITHVGGQGNNKIEKTHKLTFRENAAKTDHGAEVYKSVGSVPDSPRHLNSVSTGSDMVDSPQ-LADEVSASLAKGL</td>
</tr>
</tbody>
</table>

* designations taken from [9]

Insert 1: ESPLQPTEDGSEEPGETSDKASTPTAE
Repeat 1: QTAPVPMILNViK-NHPPGGQQVQIVKPVDSKTVSCGSLGNIHHKPGGGQVEKSEKLDKDFVQSKIG-SLDNITHVGGQGNNKIEKTHKLTFRENAAKTDHGAEVYKSVGSVPDSPRHLNSVSTGSDMVDSPQ-LADEVSASLAKGL

Insert 2: DVTAPLVEDAPGKQAAPQHEIPEGTT
Repeat 2: VQIVKPVDSKTVSCGSLGNIHHKPGGGQVEKSEKLDKDFVQSKIG-SLDNITHVGGQGNNKIEKTHKLTFRENAAKTDHGAEVYKSVGSVPDSPRHLNSVSTGSDMVDSPQ-LADEVSASLAKGL

Repeat 3: VQIVKPVDSKTVSCGSLGNIHHKPGGGQVEKSEKLDKDFVQSKIG-SLDNITHVGGQGNNKIEKTHKLTFRENAAKTDHGAEVYKSVGSVPDSPRHLNSVSTGSDMVDSPQ-LADEVSASLAKGL

Repeat 4: VEKSEKLDKDFVQSKIG-SLDNITHVGGQGNNKIEKTHKLTFRENAAKTDHGAEVYKSVGSVPDSPRHLNSVSTGSDMVDSPQ-LADEVSASLAKGL
The loose, unfolded structure prevented the determination of the exact binding site of tau to microtubules. Tau is rather stable to treatment with acids or heating [12]. Tau consists of four domains characterized by their amino acid composition and function: the N-terminal “projection domain”, a proline-rich region, the microtubule-binding part, and the C-terminal sequence [9]. The protein is a dipolar molecule, its N-terminal region contains a large proportion of acidic amino acid residues (pI 3.8), whereas the proline-rich middle part and the C-terminus are dominated by basic amino acids (pI 11.4 and 10.8, respectively) [8]. The distribution of charges can be changed by post-translational modifications associated with pathological conditions [13]. Tau exists in six major isoforms differing in number of tubulin-binding domains and length, they vary in size from 352 to 441 amino acid residues (see Table 1). They also differ in biological activity. The short isoforms allow plasticity of the cytoskeleton whereas the longer ones may preferentially play a role in its stabilization [14]. In adult human brains, the six isoforms can be found whereas in fetal brains, only the shortest isoform is expressed [15].

A central domain of tau, residues 198 to 369 for the longest isoform, aggregates with tubulin and promotes formation of microtubules. It is characterized by 3 to 4 repeat domains, all involved in binding [16] (Fig. 1). The N-terminal part is called projection domain as it projects from the surface of the microtubule. It varies in length, as 1 or 2 short sequences can be inserted. The projection domain interacts with other cytoskeletal elements and the neuronal plasma membrane, and is involved in signal transduction [17].

**Tau Pathology**

The mechanism of tau aggregation is not completely understood. Association with microtubules preserves the disordered structure of the protein. Aberrant post-translational modifications and conformational changes of tau go together with loss of affinity for tubulin and risk of aggregate formation. Phosphorylation of two or three Ser/Thr residues is required for the optimal function of tau, for retaining its unfolded structure in free form, whereas hyperphosphorylation (> 6 phosphoserines/threonines [7]) inactivates the protein. A part of the hyperphosphorylated protein aggregates yielding NFTs or tau fibers (paired helical filaments, PHFs), the rest (about 40%) remains dissolved in the cytosol disrupting microtubules [10,18]. The longest tau isoform consisting of 441 amino acids contains about 80 Ser and Thr residues, all potential phosphorylation sites. Up to now, more than 40 sites have been identified in tau isolated from AD brains. The equilibrium between phosphorylation and dephosphorylation is regulated by various enzymes, so hyperphosphorylation may also result from the inability to revert this modification of tau by action of a phosphatase. Quantitative in vitro studies demonstrated that phosphorylation of tau at Ser262, Thr231, and Ser235 inhibited microtubule binding by ~35%, ~25%, and ~10%, respectively [19]. Evaluation of the binding kinetics between hyperphosphorylated and normal tau suggested that Ser109/Ser202/Thr356, Thr212, Thr231/Ser235, Ser262/Ser356, and Ser422 could be critical phosphorylation sites that turn tau into an inhibitory molecule that destabilizes microtubules by removing tubulin-associated protein [20,21]. Further phosphorylation at Thr231, Ser396, and Ser422 promoted self-aggregation of tau into filaments.
Nε Acetylation of lysines may also be involved in the regulation of tau as well as in pathological processes [22]. This modification mediated by histone acetyltransferases (HAT) eliminates positive charges. Aberrant acetylation could interfere with the binding of tau to microtubules [23]. Acetylation of three lysine residues essential for tau binding has been detected. Acetylation of one of them, Lys280, could play a role in tangle formation [23,24]. Hyperphosphorylation promotes Nε acetylation. The side chain modification can be reverted by the NAD-dependent histone deacylase SIRT1 [25], so an equilibrium of acetylation/deacetylation could be maintained. Activity of SIRT1 is reduced in AD brains [26].

Enzymatic degradation is a major modification of tau protein in AD. Caspase-3-mediated cleavage at Asp421 [27] and further C-terminal truncation promotes maturation of NFTs [28]. The truncated proteins could serve as biomarkers for AD. N-terminal truncation at Asp13 is catalyzed by caspase-6, its role being less clear. Regular tau clearance via ubiquitinylation and degradation effected by the 26S proteasome or by autophagy is impeded in AD brains [29,30]. Glycation [31], deamidation [32], oxidation, and nitration [33,34] of tau are further modifications of the protein associated with tauopathies, whereas O-glycosylation of serine/threonine with N-acetylglucosamine reduces aberrant phosphorylation [35,36]. This beneficial modification of tau relies on an intact glucose metabolism in the brain, a condition not always met in case of AD. Accordingly, diabetes has been established as a risk factor for the disease [37].

Conformation strongly affects the enzymatic (de)phosphorylation of serines and threonines in the vicinity of a proline residue. The peptidyl-prolyl cis/trans isomerase Pin 1 isomerizes phosphoserine/threonine-proline motifs. A trans-cis conversion of the pThr231-Pro232 bond has been observed during early stages of AD. Pin1 prevents the accumulation of the resulting pathogenic cis form of tau by reverting the isomerization allowing dephosphorylation by PP2A [38]. Trans-tau promotes microtubule assembly. In AD brains, activities of both Pin 1 and PP2A are decreased [39]. An antibody developed against cis (pThr231)-tau was shown to block brain injury and tauopathy [40,41].

VQIINK (tau 275-280) and VQIVYK (tau 306-311, PHF6), two hexapeptide motifs from the N-termini of repeats R2 and R3 with a marked tendency for β-sheet formation are involved in the aggregation of hyperphosphorylated tau yielding neurotoxic polymers [24,42]. PHF formation can be abolished by incorporating proline in one of the segments [43]. The chaperone Hsp90 binds to

Even though both Aβ and tau are related to Alzheimer’s disease, studies have shown that the degree of tau-related pathology correlates better with the degree of dementia than the amyloid plaque burden.
the VQIVYK motif [44] and, together with cochaperones, assists in tau clearance via autophagy or proteasome-mediated degradation [45]. Do et al. could demonstrate that the fragments Aβ (25–35), GSNKGAIILGML, and tau (273–284), GKVQINNKDL, could interact affecting the self-assembly process of both Aβ and tau [46].

**Tau and Alzheimer’s Disease**

Aggregation of β-amyloid peptides (which result from processing of amyloid precursor protein) into senile plaques as well as formation of neurofibrillary tangles (NFT) from tau protein are associated with Alzheimer’s disease. Neither plaques nor NFT are a cause of neurodegeneration, but markers of damage and progression of AD. Nevertheless, both proteins play a central role in the development of AD and hence serve as biomarkers measured in cerebrospinal fluid [47]. It is not absolutely clear yet which of them is the real culprit responsible for eventual neuronal death. A number of observations point at tau, for example, neurofibrillary degeneration, and not β-amyloidosis, correlates with the presence of dementia in humans [48–50].

Neurofibrillary degeneration due to aberrant phosphorylation of tau could be prevented by inhibiting the involved enzymes, which makes GSK-3β, cdk5, PKA and other kinases attractive targets in developing AD cures [1,4,46]. Dephosphorylation could be promoted by upregulating PP2A, a phosphatase with broad substrate specificity.

Lithium inhibits GSK-3β, as it competes with magnesium [51,52]. In clinical studies, lithium was administered alone or in combination with valproate [53]. Further GSK-3β-inhibiting compounds as aloisines, flavopiridol, hymenialdisine, paullones, and staurosporine are under evaluation. The small molecule GSK-3β inhibitor tideglusib has reached clinical phase II for mild-to-moderate AD [54]. Aloisines and flavopiridol also inhibit cdk5, as does the purine olomucin. A reduction of tau hyperphosphorylation by administration of another purine, the selective cdk5 inhibitor roscovitine, could be achieved in mice and rats [55,56]. PP2A activity can be increased by down-regulating the two endogenous inhibitor proteins I',PP2A and I''PP2A [6,57]. The NMDA antagonist memantine, a well-established drug for the management of moderate to severe AD, reverses tau hyperphosphorylation by regenerating PP2A [58]. The antioxidant melatonin has also been shown to restore the activity of the inhibited enzyme [59,60].

Davunetide (AL-108), an octapeptide corresponding to murine activity-dependent neuroprotective protein (74–81), binds to tubulin and promotes microtubule assembly [61]. Formulations for intranasal application and injection have been evaluated in clinical studies. Clinical tests were also performed with methylene blue (methylthioninium chloride) [62]. The dye prevents tau assembly and disrupts existing aggregates, though the mode of action is not known yet [63].

Results obtained from immunotherapeutical studies using AD models are encouraging [64]. Immunizations with Aβ or tau fragments showed positive effects such as improvement of locomotor activity and ability to perform cognitive tasks. Active immunization with phosphorylated tau fragments as (pSer396,404)-Tau (379–408) [65], (pSer²⁰²,pThr²⁰⁵)-Tau (195–231), (pThr²¹²,pSer²¹⁴)-Tau (207–220), or (pThr²³¹)-Tau (224–238) [66] decreased tau pathology.

**Conclusion**

Numerous promising therapeutic approaches tackling the neuropathological effects of either aberrant tau modification or β-amyloid aggregate formation are being followed currently. This gives rise to hope that an effective cure for AD will be developed in the foreseeable future.
REFERENCES

The many faces of tau.  
Neuron 70, 410-426 (2011) Review
Tau domains, phosphorylation, and interactions with microtubules.  
Dephosphorylation of tau by protein phosphatase 5: impairment in Alzheimer’s disease.  
J. Biol. Chem. 280, 1790-1796 (2005)
PP2A regulates tau phosphorylation directly and also indirectly via activating GSK-3beta.  
Alzheimer’s disease neurofibrillary degeneration: pivotal and multifactorial.  
Tau in Alzheimer disease and related tauopathies.  
Structure and pathology of tau protein in Alzheimer disease.  
[9] E.M. Mandelkow and E. Mandelkow  
Biochemistry and cell biology of tau protein in neurofibrillary degeneration.  
J. Biol. Chem. 268, 24374-24384 (1993)
The natively unfolded character of Tau and its aggregation to Alzheimer-like paired helical filaments.  
Biochemistry 47, 10526-10539 (2008)
Physical and chemical properties of purified tau factor and the role of tau in microtubule assembly.  
Biochemistry of Tau in Alzheimer’s disease and related neurodegenerative disorders.  
[14] H. Yoshida and M.J. Goedert  
Phosphorylation of microtubule-associated protein tau by AMPK-related kinases.  
J. Neurochem. 120, 165-176 (2012)
Tau protein as a differential biomarker of tauopathies.  
[16] R. Brandt and G. Lee  
J. Biol. Chem. 268, 3414-3419 (1993)
Interaction of tau with the neural plasma membrane mediated by tau’s amino-terminal projection domain.  
[18] A.D.C. Alonso et al.  
Role of abnormally phosphorylated tau in the breakdown of microtubules in Alzheimer disease.  
Phosphorylation of tau at both Thr 231 and Ser 262 is required for maximal inhibition of its binding to microtubules.  
Promotion of hyperphosphorylation by frontotemporal dementia tau mutations.  
Alzheimer’s disease hyperphosphorylated tau sequesters normal tau into tangles of filaments and disassembles microtubules.  
[22] S.W. Min et al.  
Acetylation of tau inhibits its degradation and contributes to tauopathy.  
The acetylation of tau inhibits its function and promotes pathological tau aggregation.  
Nat. Commun. 2, 252-258 (2011)
Identification of a novel microtubule binding and assembly domain in the developmentally regulated inter-repeat region of tau.  
Paths of convergence: sirtuins in aging and neurodegeneration.  
Neuron 58, 10-14 (2008)
Tau Peptides

Sirtuin 1 reduction parallels the accumulation of tau in Alzheimer disease.

[27] T.C. Gamblin et al.
Caspase cleavage of tau: linking amyloid and neurofibrillary tangles in Alzheimer’s disease.

Tau truncation during neurofibrillary tangle evolution in Alzheimer’s disease.

[29] A.S. Chesser et al.
Tau clearance mechanisms and their possible role in the pathogenesis of Alzheimer disease.
Front. Neurol. 4, 22 (2013)

Tau degradation: the ubiquitin-proteasome system versus the autophagyllysosome system.

[31] B. Kuhla et al.
Effect of pseudophosphorylation and cross-linking by lipid peroxidation and advanced glycation end product precursors on tau aggregation and filament formation.

Deamidation and isoaaspartate formation in smeared tau in paired helical filaments: unusual properties of the microtubule-binding domain of tau.
J. Biol. Chem. 274, 7368-7378 (1999)

Site-specific nitration and oxidative dityrosine bridging of the tau protein by peroxynitrite: implications for Alzheimer’s disease.
Biochemistry 44, 1690-1700 (2005)

[34] M.R. Reynolds et al.
Nitration in neurodegeneration: deciphering the “Hows” “nYs.”
Biochemistry 46, 7325-7336 (2007)

The potential role of tau protein O-glycosylation in Alzheimer’s disease.
J. Alzheimer Dis. 6, 489-495 (2004)

Increasing O-GlcNAc slows neurodegeneration and stabilizes tau against aggregation
Nat. Chem. Biol. 8, 393-399 (2012)

[37] N. Sato and R. Morishita
The roles of lipid and glucose metabolism in modulation of β-amyloid, tau, and neurodegeneration in the pathogenesis of Alzheimer disease.

[38] C. Smet et al.
The peptidyl prolyl cis/trans-isomerase Pin1 recognizes the phospho-Thr212-Pro213 site on Tau.

[39] M. Balastik et al.
Pin1 in Alzheimer’s disease: multiple substrates, one regulatory mechanism?

[40] K. Nakamura et al.
Proline isomer-specific antibodies reveal the early pathogenic tau conformation in Alzheimer’s disease.
Cell 149, 232-244 (2012)

[41] A. Kondo et al.
Antibody against early driver of neurodegeneration cis-P-tau blocks brain injury and tauopathy.

Assembly of tau protein into Alzheimer paired helical filaments depends on a local sequence motif (306VQIVYK311) forming β structure.

[43] M.M. Mocanu et al.
The potential for beta-structure in the repeat domain of tau protein determines aggregation, synaptic decay, neuronal loss, and coassembly with endogenous Tau in inducible mouse models of tauopathy.

Hsp90 directly interacts, in vitro, with amyloid structures and modulates their assembly and disassembly.

[45] A. Salminen et al.
Hsp90 regulates tau pathology through co-chaperone complexes in Alzheimer’s disease.

Interactions between amyloid-β and Tau fragments promote aberrant aggregates: implications for amyloid toxicity.

Clinical utility and analytical challenges in measurement of cerebrospinal fluid amyloid-β(1-42) and τ proteins as Alzheimer disease biomarkers.

[48] E. Giacobini and G. Gold
Alzheimer disease therapy - moving from amyloid-β to tau.

[49] G.S. Bloom
Amyloid-β and tau: the trigger and bullet in Alzheimer disease pathogenesis.
JAMA Neurol. 71, 505-508 (2014)
[50] A. Boutajangout and T. Wisniewski
Tau-based therapeutic approaches for Alzheimer’s disease - a mini-review,
Gerontology 60, 381-385 (2014). Review

[51] W. Noble et al.
Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo.

[52] P.N. Tariot and P.S. Aisen
Can lithium or valproate untie tangles in Alzheimer’s disease?

[53] H. Hampel et al.

[54] S. Lovestone et al.
A phase II trial of tideglusib in Alzheimer’s disease.

[55] M. Kitazawa et al.
Lipopolysaccharide-induced inflammation exacerbates tau pathology by a cyclin-dependent kinase 5-mediated pathway in a transgenic model of Alzheimer’s disease.

[56] Y. Wen et al.
Cdk5 is involved in NFT-like tauopathy induced by transient cerebral ischemia in female rats.

[57] I. Tsujiro et al.
Inhibitors of protein phosphatase-2A from human brain structures, immunocytochemical localization and activities towards dephosphorylation of the Alzheimer type hyperphosphorylated tau.

[58] L. Li et al.
Memantine inhibits and reverses the Alzheimer type abnormal hyperphosphorylation of tau and associated neurodegeneration.

Effect of melatonin on calyculin A-induced tau hyperphosphorylation.

[60] L.Q. Zhu et al.
Effect of inhibiting melatonin biosynthesis on spatial memory retention and tau phosphorylation in rat.

[61] I. Gozes et al.
Addressing Alzheimer’s disease tangles: From NAP to AL-108.
Curr. Alzheimer Res. 6, 455-460 (2009)

[62] T. Gura
Hope in Alzheimer’s fight emerges from unexpected places.

[63] C.M. Wischik et al.
Selective inhibition of Alzheimer disease-like tau aggregation by phenothiazines.

[64] F. Panza et al.
Immunotherapy for Alzheimer’s disease: from anti-β-amyloid to tau-based immunization strategies.
Immunotherapy 4, 213-238 (2012) Review

[65] A.A. Asuni et al.
Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements.

[66] M. Boimel et al.
Efficacy and safety of immunization with phosphorylated tau against neurofibrillary tangles in mice.
Bachem’s offer for Alzheimer’s research comprises a broad choice of tau protein fragments and amyloid peptides. Please see also our Product Monograph “Amyloid Peptides”.

For more details on our Alzheimer’s disease peptides, please go to: shop.bachem.com
## TAU PEPTIDES

**Microtubule-Associated Protein (142-161) (human)**  
(Tau Peptide (422-441))  
H-8062 NEW  
SPQLATLADEVASLAKQGL

**Tau Peptide (1-16)**  
H-8004 NEW  
MAEPRQFEVMDMAG

**Tau Peptide (45-73) (Exon 2/Insert 1 Domain)**  
H-7804 NEW  
ESPLQTPTEDGSEEPSETSDAKSTPTAE

**Tau Peptide (74-102) (Exon 3/Insert 2 Domain)**  
H-7808 NEW  
DVTAPLVDEGAPGKQAAMQHTPEIPEGTT

**(Ser(PO₃H₂)₂02,Thr(PO₃H₂)₃006)-Tau Peptide (194-213)**  
H-8166 NEW  
RSGYSSPG(p)SPG(p)TPGRSRTTP

**(Thr(PO₃H₂)₂311)-Tau Peptide (225-237)**  
H-8048 NEW  
KVAVVR(p)TPPKSPS

**Tau Peptide (244-274) (Repeat 1 Domain)**  
H-7898 NEW  
QTAPVMPDKNVKSIGSTENLKHQP-GGGK

**Acetyl-Tau Peptide (244-274) (Repeat 1 Domain)**  
H-7808 NEW  
Ac-QTAPVMPDKNVKSIGSTENLKHQPGGGK

**Tau Peptide (245-274) (Repeat 1 Domain)**  
H-7978 NEW  
TAPVMPDKNVSKSIGSTENLKHQP-GGGK

**Acetyl-Tau Peptide (273-284) amide**  
(Ser(PO₃H₂)₃20)-Pab Blocking  
H-7966 NEW  
IG(p)STE

**Tau Peptide (268-282)**  
H-8068 NEW  
HPQGGKQVIIINKKL

**Tau Peptide (273-284)**  
H-8102 NEW  
GKVQIIINKKL

**Tau Peptide (275-305) (Repeat 2 Domain)**  
H-7812 NEW  
VQIINKNKLDLSNVQ

**Tau Peptide (277-291)**  
H-8074 NEW  
IINKLDLSNVQSKC

**Tau Peptide (279-309)**  
H-6076 NEW  
DNIKHPGGGSVQIV

**Tau Peptide (298-312)**  
H-8078 NEW  
KHVPGGGSVQIVYKYP

**Tau Peptide (301-315)**  
H-8082 NEW  
PQGGGSVQIVYKPVDL

**Tau Peptide (304-318)**  
H-8084 NEW  
GQGQIVVYKPVDLSDK

**Tau Peptide (306-317)**  
H-8096 NEW  
VQIVYKPDLSK
TAU PEPTIDES (CONTINUED)

**Tau Peptide (306–336) (Repeat 3 Domain)**
- H-7814 NEW
- VQIVYKPVDSLKVTSKCGSLGNIHHKP-GGGQ

**Biotinyl-Tau Peptide (306–336) (Repeat 3 Domain)**
- H-8028 NEW
- Biotinyl-VQIVYKPVDSLKVTSKCGSLGNI-HHKPGGGQ

**Tau Peptide (307–321)**
- H-8086 NEW
- QIVYKPVDSLKVTSK

**Biotinyl-Tau Peptide (306–336) (Repeat 3 Domain)**
- H-8088 NEW
- Biotinyl-VQIVYKPVDSLKVTSKCGSLGNI-HHKPGGGQ

**Tau Peptide (323–335)**
- H-7818 NEW
- QIVYKPVDSLKVTSK

**Tau Peptide (337–368) (Repeat 4 Domain)**
- H-7816 NEW
- VEVKSEKDFKDRVQSKIGSLDNITHVPGGGN

**Tau Peptide (379–408)**
- H-8172 NEW
- RENAKAHTDGHAEIVKSPVSVS-GDTSPRHL

(Ser(PO$_3H_2$)$_{396,404}$) Tau Peptide (379–408)
- H-8164 NEW
- RENAKAHTDGHAEIVK(p)SPVSVGD(p)SPRH

**Lys-Trp-Lys-(Ser(GlcNAc-β-D)$_{400}$)-Tau Peptide (388–411)-Lys-(biotinyl) amide**
- H-7822 NEW
- KWKHGAEIVKSSPVVS(GlcNAc-β-D)GDTSPRHSNVKK(biotinyl)-NH$_2$

**Tau Peptide (472–487)-PEG6-(507–526) (human)**
- H-7988 NEW
- RGAAPPGGKGQANATR-amino-PEG6-propionyl-KSGDRSGYSSPGTPGSR

**Tau Peptide (512–525) amide**
- H-7984 NEW
- SGYSSPGTGPNS-NH$_2$

PHF6 AND RELATED PEPTIDES

**PHF6**
- H-8098 NEW
- VQIVYK

**Acetylated PHF6KE amide**
- H-8122 NEW
- Ac-VQIVYE-NH$_2$

**Acetyl-PHF6IV amide**
- H-8114 NEW
- Ac-VQIVYK-NH$_2$

**Acetyl-PHF6QV amide**
- H-6118 NEW
- Ac-VIVYK-NH$_2$

**Acetyl-PHF6YA amide**
- H-8116 NEW
- Ac-VQIVAK-NH$_2$

**T-Peptide (all-D-PHF6-R9)**
- H-8126 NEW
- Ac-vqivykRRRRRRRRR-NH$_2$
TAU-RELATED PRODUCTS

Enzyme inhibitors and substrates and further peptides and biochemicals for Alzheimer’s research are available on our online shop shop.bachem.com

Areas of Interest
- Alzheimer’s Disease
- Tau
PIN-1 SUBSTRATES

Ac-Ala-Ala-Ser(PO₃H₂)-Pro-Arg-pNA  
**L-2155**  
Ac-AA(p)SP-pNA  

Suc-Ala-Glu-Pro-Phe-AMC  
**I-1750**  
Suc-AEPF-AMC  

Suc-Ala-Glu-Pro-Phe-pNA  
**L-1635**  
Suc-AEPF-pNA  

H-Trp-Phe-Tyr-Ser(PO₃H₂)-Pro-Arg-AMC  
**I-1930**  
WFY(p)SPR-AMC  

H-Trp-Phe-Tyr-Ser(PO₃H₂)-Pro-Arg-pNA  
**L-2075**  
WFY(p)SPR-pNA  

PKA INHIBITORS AND SUBSTRATES

cAMP-Dependent Protein Kinase Inhibitor-α (5-22) amide  
(human, mouse, rabbit, rat)  
**H-3222**  
TTYADFIASGRTGRRNA-NH₂  

H-Arg-Gly-Tyr-Ala-Leu-Gly-OH  
**M-1105**  
RGYALG  

PKA Inhibitor (6-22) amide  
**N-2040**  
TYADFIASGRTGRRNA-NH₂  

PKItide  
**H-3234**  
IAAGRTGRRQAIHDLVAA  

H-Arg-Lys-Ile-Ser-Ala-Ser-Glu-Phe-Asp-Arg-Pro-Leu-Arg-OH  
(BPDEtide)  
**H-3216**  
RKISASEFDRPLR  

Calcineurin Substrate  
**H-2084**  
DLDVIPGRFDRVSVAAE  

H-Gly-Arg-Gly-Leu-Ser-Leu-Ser-Arg-OH  
**H-7405**  
GRGLSLSR  

H1-7  
**H-1805**  
RRKASGP  

Kemptide trifluoroacetate salt  
**M-1510**  
LRRASLG trifluoroacetate salt  

Kemptide acetate salt  
**M-2725**  
LRRASLG acetate salt  

(Trp⁴)-Kemptide  
(Chocktide)  
**M-1525**  
LRRWSLG  

(Val⁶,Ala⁷)-Kemptide  
**M-1515**  
LRRASVA  

MELATONIN

Melatonin  
**Q-1300**  

N-Acetyl-2-benzyl-tryptamine  
(Luzindole)  
**Q-1885**
Perivascular cell containing tau protein.

Fluorescence deconvolution light micrograph of a section through a perivascular cell, showing tau protein (red). Tau protein is an abundant neural protein, but aggregations of this protein are thought to play a role in brain disorders such as Alzheimer’s disease. Magnification: x200, when printed 10 cm wide.

R. Bick, B. Poindexter, UT Medical School/Science Photo Library
Marketing & Sales Contact

Americas
Bachem Americas, Inc.
Tel. +1 888 422 2436 (toll free in USA & Canada)
  +1 310 539 4171
sales.us@bachem.com

Asia Pacific
Bachem Japan K.K.
Tel. + 81 3 6661 0774
sales.jp@bachem.com

Europe, Africa, Middle East and India
Bachem AG
Tel. +41 58 595 2020
sales.ch@bachem.com

Visit our website
www.bachem.com
or shop online
shop.bachem.com

All information is compiled to the best of our knowledge.
We cannot be made liable for any possible errors or misprints.
Some products may be restricted in certain countries.